These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23174638)

  • 1. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register.
    Kedhi E; Gomes ME; Lagerqvist B; Smith JG; Omerovic E; James S; Harnek J; Olivecrona GK
    JACC Cardiovasc Interv; 2012 Nov; 5(11):1141-9. PubMed ID: 23174638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
    Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials.
    Cassese S; Piccolo R; Galasso G; De Rosa R; Piscione F
    Int J Cardiol; 2011 Jul; 150(1):84-9. PubMed ID: 21315461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.
    Kitabata H; Loh JP; Pendyala LK; Badr S; Dvir D; Barbash IM; Minha S; Torguson R; Chen F; Satler LF; Suddath WO; Kent KM; Pichard AD; Waksman R
    Am J Cardiol; 2013 Oct; 112(8):1093-8. PubMed ID: 23827397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
    J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
    Räber L; Magro M; Stefanini GG; Kalesan B; van Domburg RT; Onuma Y; Wenaweser P; Daemen J; Meier B; Jüni P; Serruys PW; Windecker S
    Circulation; 2012 Mar; 125(9):1110-21. PubMed ID: 22302840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts.
    Taniwaki M; Räber L; Magro M; Kalesan B; Onuma Y; Stefanini GG; van Domburg RT; Moschovitis A; Meier B; Jüni P; Serruys PW; Windecker S
    EuroIntervention; 2014; 9(12):1432-40. PubMed ID: 24064377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents.
    Almalla M; Schröder JW; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2013 Mar; 24(2):165-70. PubMed ID: 23242011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
    Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
    J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice.
    Barbash IM; Minha S; Torguson R; Ben-Dor I; Badr S; Loh JP; Satler LF; Pichard AD; Waksman R
    J Invasive Cardiol; 2014 Apr; 26(4):154-60. PubMed ID: 24717271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stent thrombosis in early-generation drug-eluting stents versus newer-generation everolimus-eluting stent assorted by LVEF.
    van Boven N; Windecker S; Umans VA; van Domburg RT; Kardys I; Akkerhuis KM; van Geuns RJ; Serruys PW; Magro M; Räber L; Boersma E
    Heart; 2015 Jan; 101(1):50-7. PubMed ID: 25163692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.
    Omar A; Torguson R; Kitabata H; Pendyala LK; Loh JP; Magalhaes MA; Satler LF; Suddath WO; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2014 Dec; 84(7):1053-60. PubMed ID: 24619969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.
    Brener SJ; Kereiakes DJ; Simonton CA; Rizvi A; Newman W; Mastali K; Wang JC; Caputo R; Smith RS; Ying SW; Cutlip DE; Stone GW
    Am Heart J; 2013 Dec; 166(6):1035-42. PubMed ID: 24268218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.